$STXS

Stereotaxis, Inc.

Stereotaxis designs, manufactures and markets robotic systems, instruments and information systems for hospitals’ interventional laboratories. Its robotic magnetic navigation technology uses computer-controlled magnetic fields to steer the tips of flexible catheters and other devices. The company focuses primarily on electrophysiology, including cardiac mapping and ablation procedures to treat arrhythmias, and also serves other endovascular applications. Its products include Genesis and GenesisX robotic magnetic navigation systems; Odyssey, Synchrony and SynX systems for displaying, controlling, recording and sharing laboratory information; and disposable devices and accessories, including MAGiC and Map-iT catheters. Stereotaxis also offers x-ray systems through manufacturer relationships. It earns money through equipment and installation payments, disposable device sales, service and maintenance plans, warranties, and software enhancements. Stereotaxis is headquartered in St. Louis, Missouri, and operates as one business segment.

2
0
4

No SEC Form 4 filings for $STXS in the last 30 days.

See all $STXS insider activity →
Med

Stereotaxis 3Q 2026: Revenue $8.93M, EPS ($0.07) — 10-Q Summary

Stereotaxis reported 3Q 2026 revenue of $8.93M, up 20% YoY, driven by higher system sales. Net loss was $6.8M, slightly wider than the prior year. Gross margin fell to 44% from 55% due to product mix. Robocath acquisition contributed minimal revenue and a $1.6M net loss.

Why is Stereotaxis stock sliding today?

Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.

Stereotaxis (STXS) Q3 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q3 2026 revenue growth of 60% YoY, driven by sales of GenesisX and Synchrony systems. Key milestones include FDA clearance for GenesisX interoperability and a collaboration with Canon. Robotic catheter revenue is expected to reach several million dollars this year, despite supply constraints. The company anticipates resolving supply issues in early 2027 and sees growth opportunities in capital systems and disposable revenue.

STXS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning STXS (Stereotaxis, Inc.). Coverage has skewed bearish: 2 bullish, 0 neutral, and 4 bearish.

Recent STXS coverage spans earnings, technology and regulation.

What's driving STXS

AlphAI scores every news story that mentions STXS with an AI model for sentiment and relevance, and aggregates insider trades from Stereotaxis, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $STXS

Score

Why is Stereotaxis stock sliding today?

Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.

Stereotaxis (STXS) Q3 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q3 2026 revenue growth of 60% YoY, driven by sales of GenesisX and Synchrony systems. Key milestones include FDA clearance for GenesisX interoperability and a collaboration with Canon. Robotic catheter revenue is expected to reach several million dollars this year, despite supply constraints. The company anticipates resolving supply issues in early 2027 and sees growth opportunities in capital systems and disposable revenue.

$STXSMedEarnings

Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates St. Louis, November 10, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported bus

Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split

Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.

$STXSMedAI 8/10

20 robotic heart procedures had no device-related adverse events.

Stereotaxis (NYSE: STXS) announced 100% clinical success and no device-related adverse events in 20 first-in-human robotic heart procedures using Robocath's next-generation system. The study, presented at TCT 2026, showed 95% technical success and no physician radiation exposure. Robocath is a subsidiary of Stereotaxis, focusing on advanced robotic innovations for interventional cardiology.

Latvia hospital installs first robotic cardiac system

Pauls Stradiņš Clinical University Hospital in Latvia installed Stereotaxis's Genesis Robotic Magnetic Navigation System, the first of its kind in the country. The system treats cardiac arrhythmia through minimally invasive procedures. Stereotaxis (NYSE:STXS) aims to collaborate with the hospital to advance patient care and clinical science. The technology has been used to treat over 150,000 patients globally.

$STXSMedAI 8/10

Stereotaxis (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.

$STXSMedEarnings

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi

Related tickers